Biogen Inc Stock Price To Earnings To Growth
| BIIB34 Stock | BRL 154.95 1.20 0.78% |
Biogen Inc fundamentals help investors to digest information that contributes to Biogen's financial success or failures. It also enables traders to predict the movement of Biogen Stock. The fundamental analysis module provides a way to measure Biogen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biogen stock.
Biogen |
Biogen Inc Company Price To Earnings To Growth Analysis
Biogen's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Biogen Price To Earnings To Growth | 36.44 X |
Most of Biogen's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biogen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Biogen Inc has a Price To Earnings To Growth of 36.4437 times. This is much higher than that of the Healthcare sector and notably higher than that of the Drug Manufacturers - Major industry. The price to earnings to growth for all Brazil stocks is notably lower than that of the firm.
Biogen Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biogen's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biogen could also be used in its relative valuation, which is a method of valuing Biogen by comparing valuation metrics of similar companies.Biogen is currently under evaluation in price to earnings to growth category among its peers.
Biogen Fundamentals
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 | |||
| Profit Margin | 0.28 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 230.79 B | |||
| Shares Outstanding | 867.48 M | |||
| Price To Earning | 6.38 X | |||
| Price To Book | 3.28 X | |||
| Price To Sales | 21.53 X | |||
| Revenue | 10.98 B | |||
| Gross Profit | 8.87 B | |||
| EBITDA | 2.88 B | |||
| Net Income | 1.56 B | |||
| Cash And Equivalents | 3.91 B | |||
| Cash Per Share | 20.16 X | |||
| Total Debt | 6.27 B | |||
| Debt To Equity | 46.10 % | |||
| Current Ratio | 2.84 X | |||
| Book Value Per Share | 14.82 X | |||
| Cash Flow From Operations | 3.64 B | |||
| Earnings Per Share | 16.90 X | |||
| Price To Earnings To Growth | 36.44 X | |||
| Number Of Employees | 9.61 K | |||
| Beta | 0.22 | |||
| Market Capitalization | 218.2 B | |||
| Total Asset | 23.88 B | |||
| Z Score | 20.4 | |||
| Net Asset | 23.88 B |
About Biogen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biogen Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biogen Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Biogen Stock
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.